Epstein-Barr virus infection+1
RecruitingStudy on Rituximab for Preventing Epstein-Barr Virus Infection and Lymphoproliferative Disorders in EBV-Negative Kidney Transplant Patients
Study on Rituximab for Preventing Epstein-Barr Virus Infection and Lymphoproliferative Disorders in EBV-Negative Kidney Transplant Patients
- Disease:Epstein-Barr virus infectionRenal transplant
- Substances:Rituximab
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Rituximab
- Sponsor:Les Hopitaux Universitaires De Strasbourg







